Daniel P. Petrylak, MD completed his medical degree at Case Western Reserve University School of Medicine, and completed his internal medicine residency at Albert Einstein College of Medicine/Jacobi Medical center and fellowship at Memorial Sloan-Kettering Cancer Center. Since 1995, Dr. Petrylak has been the Program Director of the Genitourinary Oncology Section in the Division of Medical Oncology, Department of Medicine, Columbia University Medical Center.
He was appointed to a faculty position at Columbia University in 1991. Since appointed Program director in 1995, Dr. Petrylak focused the section on the development of novel therapeutic agents for the treatment of prostate cancer. The first phase I study of docetaxel combined with estramustine was performed by Dr. Petrylak in the Herbert Irving General Clinical Research Center.
Dr. Petrylak is involved in clinical trials research on a local, national, and international level. He is the head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak served as PI or Co PI on 7 Southwest Oncology Group Protocols. Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also help to design and served as principal investigator for the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second line therapy for hormone refractory prostate cancer.
Dr. Petrylak is a recognized international leader in the field. He has served on the program committee for the annual meetings of the American Urological Association (2003-7) as well as for the American Society of Clinical Oncology (1995-7, 2001-3). He also has served as a committee member for the Devices and Immunolgicals section of the Food and Drug Administration. He has published extensively, in the New England Journal of Medicine, Journal of Clinical Oncology, Journal of the National Cancer Institute, as well as Cancer Research and Clinical Cancer Research.

Disclosure:
Consultant, Grant/Research Support recipient – GPC Biotech, sanofi-aventis, Celgene, Cell Genesys, Dendreon
Honorarium – sanofi-aventis

Dr. Leonard Gomella is the Bernard W. Godwin, Jr. Professor of Prostate Cancer and Chairman of the Department of Urology at Jefferson Medical College. Originally from New York, Dr. Gomella completed medical school, general surgery and urology training at the University of Kentucky in Lexington, Kentucky. After a Urologic Oncology Fellowship in the Surgery Branch of the National Cancer Institute in Bethesda, Maryland he joined the faculty of Jefferson Medical College in 1988 and was appointed Chair in 2002.
Dr. Gomella is involved in both basic science and clinical research in the development of new diagnostic techniques and treatments for prostate, bladder, and kidney cancer through Jefferson’s Kimmel Cancer Center. Dr. Gomella’s team was first to use RT-PCR to detect micrometastasis in patients with prostate cancer. He serves as Associate Director of Clinical Affairs for Kimmel Cancer at Jefferson and Urology Chair for RTOG.
Dr. Gomella has authored and edited over forty books for medical students, house officers, and practicing physicians, many of which have been translated into foreign languages. He is the editor of the 5 Minute Urology Consult and co-editor of Laparoscopic Urologic Surgery, the fields’ first color atlas. Currently he is the laparoscopy editor for Glenn’s Urologic Surgery. Recovering From Prostate Cancer was the first book for the public dedicated to this topic. He has received multiple awards from organizations such as the NCI and the American Cancer Society and has been acknowledged in multiple regional and national Top Doctors publications.

Disclosure:
Speakers’ Bureau – AstraZeneca
Consultant, Investigator – GlaxoSmithKline
Investigator - Dendreon

E. David Crawford, MD is the E. David and Vicki M. Crawford distinguished professor of surgery, urology, and radiation oncology, and Head of the Section of Urologic Oncology at the University of Colorado Health Sciences Center (UCHSC) in Denver. He serves as the Senior Associate Director of the University of Colorado Comprehensive Cancer Center, also in Denver.
Dr. Crawford received his medical degree from the University of Cincinnati. His postgraduate training included an internship and residency in urology at the Good Samaritan Hospital in Cincinnati. He subsequently completed a genitourinary cancer fellowship with Dr. Donald G. Skinner at the University of California Medical Center in Los Angeles.
Dr. Crawford is a nationally recognized expert in benign prostate hypertrophy, urologic cancers, and in particular prostate cancer. The recipient of more than 69 research grants, he has conducted research in the treatment of advanced bladder cancer, metastatic adenocarcinoma of the prostate, hormone refractory prostate cancer, and other areas of urological infections and malignancies. He has authored or coauthored over 450 articles that have been published in such journals as Urology, The New England Journal of Medicine, the Journal of Urology, and the Journal of the National Cancer Institute. He has published five textbooks and authored over 50 book chapters, and is an editorial reviewer or consultant for a large number of publications, including Urology, Journal of Urology, The New England Journal of Medicine, Cancer, and the Journal of Clinical Oncology.
Dr. Crawford is an active member of many national and international organizations, including the American Society of Clinical Oncology, American Urological Association (AUA), and the American Association for the Advancement of Science. Within the AUA, he was a member of the Committee to Study Urologic Research Funding and the Prostate Cancer Clinical Trials Subcommittee. He currently serves on the board of governors, the GU committee, and the scientific advisory board of the Southwest Oncology Groups, and chairs the National Prostate Cancer Education Council. His involvement in the national prostate cancer arena has been widely recognized. Dr. Crawford has received many honors and awards, including the CaP Cure Annual Award for Scientific Presentation in 1999. In 1997, he was presented with a “Freddie Award” at the AMA International Health and Medical Film Competition for the program ITV: The Cutting Edge Medical Report (Prostate Cancer: Understanding, Diagnosing, and Defeating), which Dr. Crawford hosted with special guest retired General Norman Schwarzkopf. He again won a prestigious “Freddie Award” in 2005. He has been recognized as one of the Best Doctors of America for the past decade, and Best Cancer Doctors . This year he was awarded the honor of being selected as the Best Healthcare Provider in the Denver Metro area by the Denver Business Journal, Blue Cross, and Anthem Healthcare. In 2007, was recognized as one of the top 20 urologists in the country for men by Men’s Health Magazine.

Disclosure:
Dr. Crawford has indicated he has nothing to disclose relative to this activity.

Robert Dreicer, MD, FACP, is Chairman of the Department of Solid Tumor Oncology at the Cleveland Clinic and a Professor of Medicine at the Cleveland Clinic Lerner College of Medicine. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He received his medical degree from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Clinical Cancer Center in Madison, Wisconsin. He joined the Division of Hematology/Oncology at the University of Iowa in 1989 and upon his departure, he was a tenured associate professor of medicine and associate division director of hematology/oncology. Dr. Dreicer was appointed as a Staff Physician in Hematology/Oncology with a secondary appointment in the Urologic Institute. He was appointed Director of the Genitourinary Medical Oncology program and Associate Director of the Experimental Therapeutics Program in 2000 and Chairman of the Department of Solid Tumor Oncology in January of 2006. Dr. Dreicer has published widely in genitourinary oncology, and is the principle investigator of a large number of ongoing studies in genitourinary neoplasms. He is the Chair of the Bladder Subcommittee of the Eastern Cooperative Oncology Group and a Fellow of the American College of Physicians. He is the Chair of the Steering Committee for ASCO’s 2008 GU Oncology Meeting. He is, an Associate Editor of Urology, and a member of the editorial boards of the Journal of Clinical Oncology, the New England Journal of Medicine’s Journal Watch Hematology/Oncology and The Journal Of Supportive Oncology.

Disclosure:
Grant/Research Support recipient – Bayer, Celgene, Lilly, sanofi-aventis

Mack Roach III, MD a radiation oncologist, is an internationally renowned expert in the treatment and management of prostate cancer. His research includes new therapies such as 3-D conformal and intensity modulated radiotherapy (IMRT) as well as brachytherapy for prostate cancer. Dr. Roach chaired one of the most important clinical research trials comparing different strategies for locally advanced prostate cancer. He has gained international recognition as an authority on treatment planning for prostate cancer and served as senior author for the guidelines for treatment planning recently published by the American College of Radiology. Dr. Roach earned his medical degree from Stanford University School of Medicine. He is an active member of several professional societies including the American Society of Clinical Oncology, American Society for Therapeutic Radiology and Oncology, Radiation Therapy Oncology Group, the National Cancer Institute's IMRT Working Group and American Joint Commission for Cancer (AJCC) Staging (GU). He is a professor of radiation oncology, medical oncology and urology, and serves as the Chairman of the Department of Radiation Oncology at the University of California, San Francisco.

Disclosure:
Grant/Research Support recipient - GlaxoSmithKline
Consultant - AstraZeneca
Speakers’ Burearu - Siemens, TAP Pharma
U-56 Grant - NCI
Handbook of Evidence-based Radiation Oncology - Springer

Howard Sandler, MD is currently a Newman Family Professor and Senior Associate Chair of the Department of Radiation Oncology and Professor of Urology at the University of Michigan Medical School. He obtained his medical degree and masters of science, in physics, at the University of Connecticut and was trained in radiation oncology at the University of Pennsylvania. He is the principal investigator of a national Radiation Therapy Oncology Group (RTOG 0521) protocol studying radiotherapy and chemotherapy for prostate cancer and is the principal investigator of a NIH-funded clinical trial grant investigating novel technological aspects of prostate cancer irradiation. Dr. Sandler is also the chair of the Genitourinary Cancer Committee of the RTOG. He is an active clinical trial scientist and has used an extensive prostate cancer database to study the role of radiation therapy in the treatment of prostate cancer.

Disclosure:
Honorarium – AstraZeneca, GPC Biotech, Amgen

Oliver Sartor, MD is the Piltz Professor of Cancer Research in the Departments of Medicine and Urology at Tulane University School of Medicine. He is a medical oncologist with an interest in prostate cancer from both a basic and clinical perspective. He is on the Department of Defense Integration Panel for prostate cancer research and is the chairman-elect of the organization as well as co-editor-in-chief of the peer-reviewed journal Clinical Genitourinary Cancer. He is also the current medical oncology chair of the Radiation Oncology Treatment Group Genitourinary Cancer Committee. In addition, Dr. Sartor is a SPORE project co-PI at Dana-Farber Cancer Center on a translational project involving the clinical outcomes and consequences of the 8q24 risk alleles. Dr. Sartor's current research interests include clinical trials in advanced prostate cancer with novel agents and novel combinations of agents. His collaborative projects include novel concepts in prostate stem cells and germ line assessment of prostate cancer risk.

Disclosure:
Advisor or Review Panel member, Consultant – Cytogen, Algeta, GPC-Biotech, sanofi-aventis, GlaxoSmithKline, Ausio